Wolfe Research analyst Alex Zukin initiates coverage on Datadog (NASDAQ:DDOG) with a Peer Perform rating.
Immix Biopharma Reports 2nd Interim Clinical Trial Data Readout In Relapsed/Refractory Metastatic Colorectal Cancer In Ongoing Phase 1b/2a IMX-110 IMMINENT-01 Clinical Trial
Tumor shrinkage was observed in 3 out of 4 (75%) patients; 1 out of 4 (25%) experienced tumor control as of the July 7, 2023 clinical data cutoff date. All patients had stage IV relapsed/refractory metastatic colorectal
